Monitor upcoming clinical data readouts: topline data from OPUS-1 expected in Q4 2026, and OPUS-2/OPUS-3 data expected in first half of 2027. The strong cash position provides runway for clinical development, but continued losses are expected until potential commercialization.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $63.04entry
- T+1 · 9mo ago −4.82%α −4.28% · $60.00
- T+5 · 9mo ago −4.62%α −3.52% · $60.13
- T+20 · 8mo ago −11.31%α −6.07% · $55.91
- T+60 · 6mo ago −25.17%α −32.13% · $47.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vaxcyte reported its 2025 financial results, showing increased R&D and operating expenses leading to a larger net loss, while maintaining a strong cash position of $2.44 billion. The company highlighted clinical progress on its VAX-31 vaccine program, including initiation of three Phase 3 trials and completion of enrollment in an infant Phase 2 study, along with a recent $632.5 million equity offering that strengthens its balance sheet.
Key Financial Metrics
Key Facts
- Cash, cash equivalents and investments were $2.44 billion as of December 31, 2025, down from $3.13 billion in 2024
- Completed $632.5 million equity offering in February 2026
- Net loss was $766.6 million for 2025, compared to $463.9 million in 2024
- Research and development expenses were $794.3 million for 2025, up from $476.6 million in 2024
- Initiated three Phase 3 trials for VAX-31 (OPUS-1, OPUS-2, OPUS-3)
- Completed enrollment in VAX-31 infant Phase 2 dose-finding study with 900 infants
- No revenue or earnings guidance provided
Financial Impact
Increased R&D spending by $317.7 million year-over-year to $794.3 million, resulting in net loss expanding by $302.7 million to $766.6 million
Risk Factors
- Clinical trial setbacks could impact valuation
- Continued significant cash burn from R&D investments
- No revenue generation expected for several years as company remains pre-commercial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001649094-26-000005 |
| Document: pcvx-20260224.htm | 0001649094-26-000005 |
| Document: 0001649094-26-000005-index-headers.html | 0001649094-26-000005 |
| Document: 0001649094-26-000005-index.html | 0001649094-26-000005 |
| Document: 0001649094-26-000005.txt | 0001649094-26-000005 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $61.61 −1.27% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $61.61 −4.76% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $61.61 +12.80% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $61.61 +13.69% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers